<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Despite the high prevalence of <z:hpo ids='HP_0000822'>hypertension</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the prevalence of <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> in this population has not been determined </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: One hundred subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and resistant <z:hpo ids='HP_0000822'>hypertension</z:hpo>, defined as blood pressure &gt; 140/90 mmHg despite the use of &gt; or = 3 antihypertensive agents, were screened for <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Screening was performed by measuring the plasma <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> (PAC)-to-plasma renin activity (PRA) ratio </plain></SENT>
<SENT sid="3" pm="."><plain>Subjects with a PAC-to-PRA ratio &gt; 30 ng x ml(-1) x h(-1) underwent confirmatory salt load testing </plain></SENT>
<SENT sid="4" pm="."><plain>Diagnostic criteria included 24-h urine <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> &gt; or = 12 microg during the 3rd day of the oral salt load or a PAC &gt; or = 5 ng/dl after the 4-h intravenous saline load </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Thirty-four subjects had a PAC-to-PRA ratio &gt;30 ng x ml(-1) x h(-1) </plain></SENT>
<SENT sid="6" pm="."><plain>Fourteen subjects (14% [95% CI 7.2-20.8]) had a confirmed diagnosis of <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Ninety-three patients were African Americans </plain></SENT>
<SENT sid="8" pm="."><plain>There were no differences in age, glycemic control, and number of <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> between subjects with and without <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Subjects with <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> had lower serum <z:chebi fb="120" ids="26216">potassium</z:chebi> (3.7 +/- 0.4 vs. 4.0 +/- 0.4 mmol/l, P = 0.012), higher PAC (15.6 +/- 8 vs. 9.1 +/- 6 ng/dl, P = 0.0016), and higher PAC-to-PRA ratio (98 +/- 74 vs. 21 +/- 30 x ml(-1) x h(-1), P &lt; 0.001) than patients without <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">Primary aldosteronism</z:e> is common in diabetic patients with resistant <z:hpo ids='HP_0000822'>hypertension</z:hpo>, with a prevalence of 14% </plain></SENT>
<SENT sid="11" pm="."><plain>Our results indicate that diabetic subjects with poorly controlled <z:hpo ids='HP_0000822'>hypertension</z:hpo> who are taking &gt; or = 3 antihypertensive drugs should be screened for <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e> </plain></SENT>
</text></document>